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Abstract  
Transgenic mouse models have vastly contributed to our 
knowledge of the genetic and molecular pathways underlying the 
pathogenesis of neurological disorders that affect millions of people 
worldwide. Not only they have allow the generation of disease 
models mimicking the human pathological state but they have also 
permit the exploration of the pathological role of specific genes 
through the generation of knock-out and knock-in models. Classical 
constitutive transgenic mice have several limitations however, due 
to behavioral adaptation process occurring and conditional mouse 
models are time-consuming and often lack of extensive spatial or 
temporal control of gene manipulation. These limitations could be 
overcome by means of innovative methods that are now available 
such as RNAi, viral vectors and large cloning DNA vectors. These 
tools have been extensively used for the generation of mouse 
models and are characterized by the superior control of transgene 
expression that has proved invaluable in the assessment of novel 
treatments for neurological diseases and to further investigate the 
molecular processes underlying the etiopathology of neurological 
disorders. Furthermore, in association with classical transgenic 
mouse models, they have allowed the validation of innovative 
therapeutic strategies for the treatment of human neurological 
disorders. This review describes how these tools have overcome the 
limitations of classical transgenic mouse models and how they have 
been of value for the study of human neurological diseases. 
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1. Introduction 
Neurological disorders are a family of more than 600 different 
diseases that affect millions of people worldwide. Due to the 
extension of life expectancy and aging of population, the occurrence 
of these diseases in the future is likely to increase. Our knowledge 
of the molecular pathways underlying the pathogenesis of this wide 
class of disorders has been remarkably improved through the use of 
transgenic mouse models [1]. These animal models have played an 
important role in the study of neurological diseases thanks to the 
possibility to stably introduce normal or modified genes into, or 
indeed, eliminate genes from a living organism. They have allowed 
the generation of disease models that resemble the human 
pathological state and provided convincing tools to test and validate 
new possible therapeutic approaches [2]. They have also lead to the 
exploration of the pathological significance of a putative target gene 
in neurological disorders. Recently, thanks to the advent of several 
functional genomic technologies such as microarray-based analysis 
or proteomic platforms a wide number of putative genes, potentially 
involved in a specific disorder have been identified. However the 
effective patho-physiological significance of these genes requires in 
vivo validation. One of the methods most broadly used for in vivo 
target validation is the genetic manipulation of the gene of interest 
and the analysis of the resulting behavioral phenotype and/or of the 
physiological alterations. Traditionally transgenic animal models 
were created through homologous recombination in embryonic stem 
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(ES) cells such that the gene of interest was either stably knocked 
out or over-expressed in mice. However the traditional transgenic 
mouse models carrying constitutive mutations were often associated 
with several disadvantages such as genetic compensation and 
developmental adaptations that could mask a clear phenotype [3]. 
Therefore in the last decades an extensive research has been carried 
out to develop technical strategies that allow the introduction or 
suppression of a target protein in a spatial and temporal manner. In 
this context tissue-specific transgenic expression or the use of 
inducible systems to temporally control transgene expression have 
been successfully applied to generate mice models beneficial for 
deepening our knowledge of the etiology of neurological disorders 
[4]. Nowadays several innovative methods for gene manipulation 
such as RNA interference (RNAi), viral vectors and DNA vectors as 
yeast-derived artificial chromosomes (YACs) or bacterial-derived 
artificial chromosomes (BACs) have became available and have 
been successfully employed to create more sophisticated animal 
models which have been invaluable for the study of neurological 
disorders (Fig. 1) [5-7]. These modern technologies offer the main 
advantage of allowing rapid and specific genetic manipulation in 
several species compared with the classical transgenic methodology. 
This review describes the application of these innovative methods in 
developing mouse models for neurological disorders and how they 
have overcome some of the restrictions of embryonic genetic 
manipulation. 
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2. RNA interference  
RNAi is an evolutionary conserved natural process of post-
transcriptional gene silencing, first demonstrated by Fire and 
colleagues in 1998 in the worm Caenorhabditis elegans [8]. RNA 
interference is defined as the process by which double-stranded 
(ds)RNA molecule silences gene expression, either by inducing the 
degradation or destabilization of complementary mRNA or by 
inhibiting translation. Although it is only a recent discovery, RNAi 
has soon become an important tool in drug discovery and had 
opened several biological applications and new therapeutic 
strategies. Tuschl and colleagues in their studies of RNAi processes 
in Drosophila melanogaster embryo extracts showed that long 
dsRNA substrates could be cleaved into short interfering dsRNA 
species (siRNAs) of ~22 nucleotides (nt), able to anneal to the target 
mRNA driving its degradation. They also showed that the 
introduction of a chemically synthesized siRNA of 21-22nt to these 
extracts facilitated the degradation of the homologous target 
mammalian genes [9], thereby evading the interferon response. 
Another technical advance came from the demonstration that 
siRNAs could be endogenously expressed in the form of short 
hairpin RNAs (shRNAs) by a DNA vector transfected into a cell. 
The vector contains a shRNA cassette with a promoter that drives 
the transcription of a fold-back stem-loop RNA structure. This 
shRNA is then processed to siRNA by the RNAi machinery and is 
therefore able to induce target-gene silencing in mammalian cells. In 
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addition to its power as a tool for gene silencing in biology, RNAi is 
also a conserved endogenous system of gene expression regulation 
through micro RNAs (miRNAs) [10,11]. miRNAs have been cloned 
from various organisms and cells (the first identified was lin-4 from 
C.elegans) and in vertebrates miRNAs are currently estimated to 
comprise 1% of animal genes [12]. Through experiments of over-
expression or knockdown of individual miRNA, it has been 
demonstrated that miRNAs affect the mRNA levels of many genes 
and regulate several cellular processes, such as the control of 
cellular state and the developmental process [13]. Recent evidences 
suggest that a large number of miRNAs are expressed in the 
mammalian brain in a spatio-temporal  manner, suggesting a crucial 
role of these molecules in regulating brain development and 
neuronal cell fate [11,14]. In fact, conditional transgenic mice 
lacking the activity of Dicer, the enzyme necessary for the miRNA 
synthesis, die postnatal due to neural hypotrophy [15]. Evidence 
suggests that each miRNA potentially controls the expression of 
hundreds of mRNAs in the brain, suggesting the presence of 
feedback control loops or indicating moderate modification at the 
level of target proteins expression. Not surprisingly several miRNAs 
have been shown to be associated with different neurological and 
psychiatric disorders since even subtle modifications of neuronal 
physiology of the human central nervous system (CNS) may be 
associated with strong effects on cognitive or neurological functions 
[16,17].  
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2.1 RNAi machinery 
The miRNAs have been shown to share much of the same 
machinery of siRNA-induced gene silencing that is characterized by 
evolutionary conserved enzymes. The siRNAs, characterized by 2nt 
3’ overhangs and 5’-phospate and 3’-hydroxyl groups, are 
incorporated in the multi-protein complex known as the RNA-
induced silencing complex (RISC) that unwinds the duplex siRNA 
into single stranded siRNA, using an ATP-dependent RNA-helicase 
activity. The antisense strand of the duplex guides the RISC 
complex to the homologous mRNA, targeting it for degradation 
(Fig. 2a). As previously seen, the siRNAs can also be generated in 
the cytosol by the evolutionary-conserved Dicer enzyme, starting 
from longer dsRNA molecules in the form of a hairpin structure. 
These shRNAs can be produced from a DNA template under the 
control of RNA polymerase (pol) II or III promoters (Fig. 2b). The 
siRNA produced from the shRNA construct is then recognized by 
the endogenous RNAi machinery and is therefore able to induce 
target-gene silencing in mammalian cells. The miRNAs are 
endogenous short single stranded RNAs of roughly 22nt produced 
by cleavage of longer (~70nt) endogenous precursors with imperfect 
hairpin RNA structure (pre-miRNA) by the Dicer enzyme (Fig. 2c), 
which suppress the expression of partially complementary target 
mRNAs by translation inhibition or mRNA destabilization rather 
than mRNA degradation [10].  
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2.2 RNAi application for neurological disorders 
Neurological disorders are often associated with mutations at 
the level of specific genes. In some cases the mutant genes are 
associated with an abnormal gain of function that leads to the 
pathological state. In this context, the advent of interfering processes 
naturally silencing the expression of specific gene could help in 
understanding the pathological process or investigating the 
therapeutic potential of the target gene. Moreover, conditional 
genetic manipulation techniques that allows the creation of mouse 
models with a spatial and temporal control over gene expression 
often lack of sufficient spatial control and are time consuming. In 
this context, RNAi can be used to generate localized gene 
knockdown in mouse brain for rapid production of new genetic 
disease models of interest for neurological disorders. 
RNAi offers several advantages as tools for gene manipulation 
over other silencing technologies such as the conventional antisense 
or the ribozyme methods such as higher specificity, versatility 
(interfering RNA can be designed virtually against any gene), and 
efficiency (in many cases, genes can be silenced by over 90%). 
Moreover since it does not induce the complete silencing of the 
target gene, it allows it to mimic the pharmacological manipulation 
of the gene itself [18]. However the generation of neurological 
models using RNAi faces a major problem of in vivo brain delivery 
since the blood-brain-barrier limits the passive entry of materials 
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from the peripheral circulation. The methodologies for RNAi 
application in mouse brain are essentially two: direct pre-
synthesized or chemically modified siRNAs delivery using several 
carriage systems or prolonged vector-mediated siRNA production. 
The simplest way to deliver siRNAs is to locally inject them in the 
desired region of the brain. Successful gene knockdown in mouse 
brainstem and hypothalamic nuclei has been reported with this 
method, but only a transient and highly restricted suppression 
around the injection site was achieved [19]. Transfection reagents 
such as nanoparticles, liposomes or other cationic carriers able to 
efficiently deliver siRNA in the mouse brain have been recently 
described [20,21]. As example, Peters and colleagues employed 
polyethyleneimine (PEI) to deliver siRNAs targeting cyclic AMP 
responsive element-binding protein (CREB) and protein 
phosphatase 1 (PP1) into the dorsal hippocampus of mice, in order 
to investigate the role of these genes in mediating contextual 
memory formation [22]. However these methods have been reported 
to be associated with neurotoxic effects [23]. Alternatively, 
electroporation can be used for siRNA-delivery and subsequent 
gene silencing [24], but very few reports in the literature describe 
the real efficacy of these approaches to study neurological disorders. 
Recently, Thakker and colleagues have successfully applied the 
osmotic mini pump technology to efficiently deliver siRNAs and 
mediate gene silencing throughout the whole mouse brain and 
without neurotoxic effects [25-27]. The siRNA released from the 
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pump by the osmotic pressure, is directed via a catheter to a 
stereotaxically placed cannula for infusion into the brain, resulting 
in prolonged siRNA administration and diffusion throughout the 
whole brain. The dopamine transporter (DAT) protein was reduced 
in the substantia nigra compacta and ventral tegmental area after 
infusion of an unmodified siRNA into the dorsal third ventricle of 
mice over a 2-week period. DAT suppression was associated with a 
time-dependent hyperlocomotor phenotype, similar to that obtained 
after infusing a pharmacologically-selective DAT inhibitor. DAT is 
the key modulator of dopamine release into the synapse and is 
therefore implicated in the control of dopamine action on 
locomotion, emotion, reward and cognition. Similarly, suppression 
of the serotonin transporter (SERT) gene, implicated in the etiology 
of anxiety and depression, was achieved after a 2-week siRNA 
infusion into the dorsal third ventricle. This decrease was reflected 
in an antidepressant-like behaviour in the mouse forced swim test, 
an effect identical to that obtained from mice receiving a 
pharmacologically-selective SERT inhibitor. Indeed, the application 
of RNAi to suppress SERT in adult mouse brain represents a major 
advantage over the classical SERT knock-out mouse model since 
these knock-out mice display a paradoxical depression-related 
behavior probably due to developmental adaptations deriving from 
early life absence of SERT [28]. Therefore RNAi-induced 
knockdown provides a superior model for investigating the role of 
SERT in the adult brain in an easier and less difficult time-
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consuming manner compared to the generation of conditional 
knock-out animals. Similarly, osmotic mini pumps were used for 
siRNA-induced knockdown of the metabotropic glutamate receptor 
7 (mGluR7) to investigate the role of this receptor in the extinction 
of aversive memories in two different amygdala-dependent tasks 
[27]. Overall these data showed the efficacy of osmotic mini pump 
in delivering siRNAs in the mouse brain to produce specific and 
bilateral knockdown of gene expression and this is particularly 
useful when the pattern of expression of the target gene is 
widespread in the brain or is not completely understood [29]. 
However a big disadvantage of this method is that it requires a large 
amount of chemically-modified siRNA in order to produce 
sustained silencing due to the relative instability of RNA molecules.  
Direct delivery of siRNAs to the peripheral nervous system 
(PNS) is less demanding compared to the brain since the PNS is 
more amenable to deliver to than the CNS and has been successfully 
employed in the study of neuropathic and visceral pain. For 
example, siRNA targeting the vanilloid receptor 1 (TRPV1) was 
directly injected intrathechally into a mouse model of visceral pain 
producing a significant analgesic effect similar to the reduction of 
pain sensitivity observed after administration of an analgesic 
compound [30].  
 
2.3 Vector-mediated RNAi 
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One of the major disadvantages of using pre-synthesized 
siRNA in vivo is the transient nature of gene knockdown since small 
RNA molecules are relatively unstable in the extracellular and 
intracellular environment due to the presence of RNA degrading 
enzymes (RNAses). Double stranded RNA is more stable than 
single strand RNA and even though chemical modifications 
increasing the stability of siRNA have been reported, these have, so 
far, not allow prolonged gene silencing in vivo. Consequently, DNA 
vectors with RNA pol III promoters such as the RNase P H1 or the 
U6 small nuclear promoter have been developed to constitutively 
express shRNAs in order to achieve a long-lasting siRNA 
production intracellularly. RNA pol III promoters efficiently direct 
the synthesis of small non-coding RNA with well defined ends but 
transfer RNA (tRNA) promoters and RNA pol II-based 
cytomegalovirus (CMV) promoters have been also successfully used 
[31]. Recently, several groups employed miRNA-based expression 
cassettes to express artificial miRNAs resembling the stem loop 
structure of endogenous precursor miRNA allowing these artificial 
miRNAs to enter the miRNA pathway and to be processed into very 
high level of mature miRNAs. These artificial miRNAs have been 
shown to effectively silence target gene expression and miRNA-
expressing vectors have been developed based on an artificial 
miRNA scaffold derived from human miR genes and are now 
commercially available [32]. Few cases of the delivery of shRNA- 
or miRNA-plasmids using transfection agents or electroporation 
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have been reported as these have lead to neurotoxic effects. For 
example, Makimura and colleagues reported the transient silencing 
of agouti-related protein (AGRP) in the hypothalamic arcuate 
nucleus of adult mice with liposomal transfection of an H1 
promoter-driven shRNA expression vector [19]. Osmotic mini 
pumps have been employed to deliver siRNA-expressing plasmids 
to neural neoplastic cells in order to investigate the effect of 
silencing potential oncogenic proteins in brain tumor growth and 
invasion. Lakka and colleagues employed osmotic mini pump to 
deliver a CMV-promoter plasmid expressing siRNAs against 
urokinase-type plasminogen activator receptor (uPAR) and matrix 
metalloproteinase-9 (MMP-9) in glioblastoma-bearing nude mice 
[33]. siRNA expression resulted in a total regression of the pre-
established intracerebral tumor growth, demonstrating that RNAi 
could be an effective tool to target genes involved in tumor cell 
invasion. Recently, encapsulated and coated siRNA-expression 
vectors, able to cross the blood-brain-barrier, have been developed 
as a potential new gene therapy for silencing oncogenic genes in 
brain cancer [34]. These vector-encapsulating liposomes (PILs) are 
externally conjugated to polyethylene glycol (PEG) to extend their 
half-life in the bloodstream and bind receptor-specific 
peptidomimetic monoclonal antibodies that facilitate brain-specific 
delivery. Encapsulated plasmids expressing siRNA targeting the 
epidermal growth factor receptor (EGFR) were injected 
intravenously in adult severe combined immunodeficient mice 
 14
implanted with human U87 gliomas. The targeted gene was 
successfully silenced and the survival time of shRNA-expressing 
mice approximately doubled, suggesting the efficacy of this strategy 
for experimental as well as therapeutic knockdown of oncogenes in 
the brain tumours [35].  
Undoubtedly the most investigated method to deliver and 
express siRNA or miRNA in the brain is by means of recombinant 
viral vectors. Viruses are naturally evolved gene vehicles that can be 
engineered for the delivery of the desired sequences into host cells. 
The several viruses available ensure broad tropism and efficient 
transduction of different mammalian cells (Table 1). In the main, the 
viral vectors that have been employed to mediate prolonged RNAi 
in the brain are derived from lentivirus (LV), adenovirus (Ad), 
adeno-associated-virus (AAV) and herpes simplex virus (HSV). 
Given their inability to transduce non-dividing or post-mitotic cells, 
the use of oncoretroviruses for targeting neuronal gene expression in 
vivo is limited. On the contrary, recombinant LV vectors based on 
both human immunodeficiency virus (HIV-1) and equine infectious 
anaemia virus (EIAV) have been successfully employed to obtain 
long-term expression of siRNAs and subsequent gene silencing in 
the brain [36]. In the first proof-of-concept study, an HIV-1-derived 
lentiviral vector expressing a shRNA targeting the enhanced green 
fluorescent protein (eGFP) under the control of a U6 promoter was 
injected into the striatum of adult mice [37]. One week after 
injection, eGFP expression from a co-injected eGFP-encoding 
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lentiviral vector was completely silenced. Recently, lentiviral-
mediated RNAi in mice was employed to investigate the potential of 
a new therapeutic approach for refractory epilepsy through focal 
cell-mediated release of adenosine to effectively suppress seizures 
by local augmentation of the adenosine system. Lentiviral constructs 
were used for the expression of anti-adenosine kinase (ADK) 
targeting miRNAs to mediate downregulation of ADK, the major 
adenosine-removing enzyme, in human mesenchymal stem cells 
(hMSCs), which would be compatible with autologous cell grafting 
in patients [38]. Adult mice that underwent the implant of hMSCs in 
hippocampus were less susceptibility to seizures, demonstrating the 
efficacy of this approach for the generation of patient identical 
autologous adult stem cell grafts for the treatment of epilepsy. 
Similarly, lentiviral-mediated RNAi was employed to silence a 
neuronal cell adhesion molecule, L1CAM, in glioma cells before 
injection into immunocompromised mice or directly in the 
established tumor. The L1CAM-siRNA expression resulted in 
suppression of tumor growth and an increase in the survival of 
tumor-bearing animals thus confirming the potential of both viral 
and non-viral RNAi gene therapy for the treatment of human brain 
cancer [39]. Adenoviruses and adeno-associated viruses (AAV) are 
single and double-stranded DNA viruses, respectively, which 
exhibit comparable transduction efficiencies in neuronal cells to 
lentiviruses. Local injections of recombinant adenoviral shRNA 
constructs have been shown to induce substantial knockdown of 
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eGFP expression in the striatum of adult eGFP-expressing mice 
[40]. AAV-based vectors have been also extensively used to 
mediate neuronal RNAi in mice for the study of neurological 
disorders. Hommel and colleagues investigated the effect of tyrosine 
hydroxylase (TH) silencing in the substantia nigra compacta and 
ventral tegmental area of adult mice [41]. TH is a key enzyme for 
the production of dopamine and the degeneration of dopaminergic 
neurons in the midbrain substantia nigra compacta is the primary 
cause of Parkinson disease. Hommel et al developed AAV-shRNA 
vectors targeting TH mRNA and reported shRNA-mediated 
downregulation of TH that persisted for a period of up to 50 days 
post-transduction and rostrocaudally spread across the substantia 
nigra compacta. This localized gene knockdown was coupled to a 
modified behaviour, in specific a motor-deficit and a reduced 
response to psychostimulant.  
 
2.4 Viral-vector mediated RNAi for neurodegenerative disorders 
Despite the useful application of RNAi in investigating the 
functional role of target genes in a specific behaviour or a 
physiological process, a major application of viral vector-mediated 
RNAi in the brain has been the exploration of the potential 
therapeutic efficacy of RNA interference for neurodegenerative 
disorders. Thanks to the high specificity of RNAi-mediated gene 
silencing, RNA interference has shown therapeutic efficacy in 
several mouse models of human neurological conditions [42]. 
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Moreover, in combination with the long-lasting expression of 
siRNAs achieved by viral vectors, it represents a promising 
therapeutic option for treating neurodegenerative diseases [43]. 
Several groups have employed RNAi to target dominantly-inherited 
genes associated with neurodegenerative disorders such as 
spinocerebellar ataxia (SCA), Huntington’s disease (HD) and 
Amyotrophic Lateral Sclerosis (ALS). Dominant mutations in the 
human Cu/Zn superoxide dismutase (SOD1) gene, one of the causes 
of familial ALS, lead to progressive death of motoneurons through a 
gain-of-function mechanism. The efficacy of RNAi to silence the 
pathogenic SOD1 mutant gene in ALS mice has been reported by 
three independent groups. In mice expressing a mutated form of 
SOD1 (SOD1G93A), increase in the survival and function of motor 
neurons and a marked reduction in the muscular atrophy was 
observed after intraspinal injection of SOD1-shRNA expressing 
lentiviral vector [44]. Similarly, an EIAV-based lentiviral vector 
[45] and an AAV2 vector [46], both expressing a shRNA against 
SOD1 mutant, when injected into the muscle of mouse models of 
ALS, have producing similar therapeutic effects. These results show 
that intramuscle or intraspinal delivery of a viral vector silencing 
SOD1G93A provided a considerable therapeutic benefit in ALS 
mouse models by delaying beginning of motor neuron impairment 
and prolonging neuron survival. Nonetheless, a major hurdle of viral 
vector-mediated RNAi therapy for humans is the invasive delivery 
of viral vectors in the target neuronal population which would 
 18
require surgical intervention. Recently AAV6 vectors expressing 
shRNA targeting SOD1 was delivered intravenously (i.v.) in 
SOD1G93A mice, inducing a significant reduction in SOD1 protein 
in the muscles but without altering the time course of the disease. 
This demonstrated the limited efficacy of viral vector-mediated 
RNAi for treating neurodegenerative disorders if the viral vectors 
are delivered i.v. [47]. Similarly, several studies reported efficacy of 
RNAi in treating animal models of polyglutamine disorders, such as 
Huntington’s disease and SCA1. These disorders are induced by 
expanded CAG repeat mutations in the genes for the huntingtin or 
ataxin-1 proteins, resulting in abnormal polyglutamine stretches 
which confer a disabling neurotoxic gain-of-function in HD or 
SCA1 respectively. Recombinant AAV-shRNA vectors were 
reported to efficiently silence the mutant huntingtin in the striata or 
cerebellar lobules of murine models of HD and the successful 
protein suppression was associated with a significant reduction in 
the HD neuropathology [48-50]. AAV vectors have also been used 
to express siRNAs targeting a specific isoform of acid-sensing ion 
channel (ASIC) in a mouse model of HD.  The RNAi-mediated 
ASIC silencing resulted in a decreased aggregation of the mutated 
huntingtin in the striatum of HD mice [51]. Thus, these studies 
provide evidence of the potential efficacy of viral vector-mediated 
RNAi for post-symptomatic HD therapy. Similarly, recombinant 
AAV vectors, expressing human ataxin-1-targeting shRNA from the 
H1 promoter, have been injected at multiple sites in the midline 
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cerebellar lobules of SCA1 mice, expressing the human ataxin-1 
disease allele in cerebellar Purkinje cells [52]. Using this approach, 
successful target gene suppression was achieved, together with a 
significant improvement in motor performance even if only a small 
percentage of all the cerebellar Purkinje cells were transduced with 
the shRNA-expressing AAV. Alzheimer’s disease (AD) is a 
progressive neurodegenerative disorder affecting the elderly and 
characterized by the accumulation of amyloid-β protein (Aβ) in the 
CNS. A great deal of effort has been made recently to develop 
treatments reducing the accumulation of amyloid-β in the brain of 
AD patients that leads to neuronal dysfunction and eventually to 
neuronal death. Several independent groups have reported the 
efficacy of viral vector-mediated RNAi to directly reduce expression 
of amyloid precursor protein (APP) or silence genes involved in 
APP processing. Hong and colleagues developed HSV vectors 
inhibiting the accumulation of Aβ by expressing APP-targeting 
shRNA. These workers initially over-expressed the APP protein 
through injection of LV-APP vectors in hippocampus and then 
observed a significant inhibition of Aβ deposits in the mouse brain 
after treatment with the HSV-APP/shRNA vectors but not with the 
control vector [53]. However since the functional role of APP in 
normal adult brain is not clear, silencing APP function could 
represent a uncertain therapeutic strategy as it could lead to 
physiological alterations in the treated brain. Abnormal activity of 
the β-secretase enzyme BACE1 has been associated with the 
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accumulation of Aβ and with the neurodegenerative process in the 
brain of AD patients. Injection of lentiviral vector expressing a 
siRNA against BACE1 reduced both APP cleavage and the 
neurodegenerative process in the brain of APP transgenic mice [54]. 
Using this approach the BACE1 activity was reduced but not 
completely abolished. Similarly, lentiviral-mediated RNAi has been 
employed to investigate the effect of angiotensin II (AT2) receptors 
silencing in hippocampus of a mouse model of Alzheimer disease. 
AT2 silencing was associated with a decreased Tau phosphorylation 
and Aβ aggregation, demonstrating the important role of Aβ-
induced AT2 oligomers as a previously unrecognised sign of 
ongoing neurodegeneration in AD [55]. Parkinson’s disease (PD) is 
one of the most common neurological disorders, caused by the death 
of dopaminergic neurons in the substantia nigra (SN) that provide 
dopamine input to the striatum. Since the localized area of 
intervention and the discrete number of neurons that have to be 
targeted, RNAi could represent a valid therapeutic approach for this 
disorder [56]. Overall results confirm the ability of siRNA-
expressing viral vectors to mediate sustained and prolonged 
suppression of target gene in specific brain area which can be 
invaluable either to study or to treat neurodegenerative disorders. 
However, the potential benefit of RNAi as therapeutic strategy for 
human patients of neurological diseases could be limited by safety 
factors. Recently, Grimm and colleagues reported fatal side effects 
in mice induced by AAV-mediated shRNAs expression after low-
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pressure i.v. vector injection [57]. Lethal effects were observed only 
with certain shRNA constructs and were not related to the target 
gene of the shRNA itself. In the past RNA interference were shown 
to induce immune response and off-target effects under certain 
conditions but the proper design of the siRNA or shRNA sequences 
can avoid or limit these side outcomes. However, the fatal effects 
reported by Grimm and colleagues seem to be probably induced by 
a competition with the endogenous microRNA pathway for post-
transcriptional gene regulation [58]. Similarly, McBride and 
colleagues reported severe neurotoxic effects in mouse striatum 
induced by certain shRNA constructs, not related to the silencing 
efficacy or to the target gene of the shRNA itself. This shRNA 
neurotoxicity, presumably induced by the high levels of antisense 
RNA generated in mouse brain only by certain shRNA constructs 
was mitigated when the same sequences were placed into artificial 
miRNA expression systems [59]. Moreover, the difficulties of 
delivery of the siRNA-expressing vectors to the brain and the safety 
concerns associated with the use of viral vectors could limit the 
application of RNAi-based therapy in humans. Nonetheless, RNAi 
still remains a promising therapeutic approach for the treatment of 
neurodegenerative disorders and recent progress in non-viral siRNA 
delivery could represent a solution in overcoming the blood-brain-
barrier and successfully delivering the siRNA into the brain. 
 
2.5 Transgenic RNAi 
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In addition RNAi has been successfully employed for the 
generation of prolonged, stable, loss-of-function phenotypes through 
shRNA-mediated transgenic RNAi. shRNA expressing vectors have 
been transfected into mouse ES cells using electroporation to 
generate stable integrants with target gene knockdown that could be 
then injected into blastocysts. Furthermore, stable passage of the 
shRNA-expressing vector from the ES cells to adult mice and 
germline transmission to the F1 progeny has been demonstrated 
[60]. Since lentiviral vectors can infect mouse ES cells and are 
believed to be resistant to proviral silencing during development, 
they have been used for transducing ES cells with the shRNA-
expressing constructs [61,62]. To overcome the limitations of the 
constitutive and widespread gene knockdown of transgenic RNAi 
animals, the Cre–loxP recombination system has been employed to 
control the spatial-temporal expression of shRNAs. In this system, 
the shRNA-expressing vector is modified in order to incorporate a 
specific sequence that prevents transcription from the vector, 
flanked by loxP sites. Since these sites are recognized by the Cre 
recombinase, the original open reading frame of the vector is 
restored only by a Cre-mediated recombination event. Using 
inducible Cre expression systems, such as those controlled by 
tetracycline or tamoxifen, along with transgenic RNAi, it could be 
possible to investigate the phenotypical outcome for brain-specific 
genes loss of function with temporal and spatial specific control. 
This approach possesses several advantages over gene knockout 
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approach by homologous recombination since is faster, cheaper and 
is applicable to several mammalian species [63]. Zhou and 
colleagues employed transgenic RNAi to investigate the effect of 
silencing a Parkinson disease-associated gene, the PTEN-induced 
putative kinase 1 (PINK1) in the mouse brain. They developed 
RNAi transgenic mice with inducible expression of a PINK1-
targeting shRNA using the Cre-loxP inducible U6 promoter. The 
expression of PINK1 was effectively silenced by more than 95% in 
mouse brain after shRNA induction but this did not result in loss of 
dopaminergic neurons, suggesting that loss of PINK1 gene 
expression in mice is not sufficient to induce Parkinson’s disease 
phenotypes [64]. The results showed also the validity of the Cre-
loxP regulated U6 promoter for conditional gene silencing in vivo, 
since shRNA expression was widespread in all tissues of the 
transgenic mice only after Cre induction.  
 
3. Viral vectors 
Viral vectors are commonly used in a wide number of 
applications, such as gene therapy to restore normal function or for 
gene expression modulation to investigate the function of a target 
gene or to confirm its involvement in a disease mechanism [65]. 
They offer the advantage of manipulating gene expression in a wide 
range of mitotic and post-mitotic cells and to mediate persistent 
expression of the delivered genetic sequences (Table 1). Among the 
different viral types, retroviruses are RNA viruses which reverse-
 24
transcribe their RNA viral genome into double stranded DNA that is 
then stably inserted into the host genome. They mediate high gene 
transfer efficiency, low immunogenicity and mediate persistent 
expression of the transgene. However, due to their ability to 
integrate into host DNA they could be associated with risk of 
insertional mutagenesis. DNA viruses contain a single- or double-
stranded DNA genome. The most predominant viruses used are the 
Adenovirus, AAV and HSV thanks to their broad cell tropism and 
efficient infection and gene transfer. Viral vectors based on 
adenovirus possess the advantages of having large insert capacity 
and relative ease of manipulation. On the other hand, their in vivo 
use has been limited by vector-associated immunotoxicity, 
inflammation, and transient transgene expression [66]. AAV-based 
vectors are attractive for their low immunogenicity and the ability to 
persist as stable episomal form in the infected cells, allowing lasting 
transgene expression without risk of insertional mutagenesis. 
Moreover, their small size makes them ideal for application 
requiring diffusion into wide brain area. A disadvantage is their 
limited insert capacity, which can be an obstacle if it is required the 
expression of large transgenic insert. HSV is of interest because of 
its large insertional capacity for foreign DNA, its natural tropism 
toward neurons, its relative stability and long-term expression of 
transgenes, particularly in neurons. However HSV vectors have 
associated with toxicity after viral infection. More recently, 
numerous new viral vectors have been developed based on vaccinia 
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virus, human cytomegalovirus, Epstein-Barr virus and others but 
their used in vivo is still limited [65].  
 
3.1 Viral vector applications for neurological disorders 
In recent years, viral vectors have been extensively used for 
the generation of mouse models of interest in the study of 
neurological disorders. As previously described, viral vectors have 
been effectively employed to mediate persistent RNAi in the brain 
for the generation of animal models with selective target gene 
silencing or to validate RNAi-based therapeutic approaches in 
mouse model of gain-of-function neurodegenerative disorders. In 
addition, they have been employed for the study and for the 
treatment of those disorders characterized by a loss-of-function 
mechanism and for the generation of mouse models for gain-of-
function disorders, through persistent delivery of the therapeutic 
gene. They can be employed for either inducing persistent genetic 
manipulation in the whole body through transduction of the mouse 
germ line or in specific area of the central nervous system through 
intracerebral injection. Several routes for viral vectors delivery in 
the brain are available: intracerebral stereotaxic injection, intrathecal 
and intraventricular injection and intravascular infusion with or 
without modification of the blood-brain-barrier. The choice of route 
for viral vectors administration needs to be carefully considered 
since it affects neuronal cells transduction efficiency and spatial 
distribution, as well as the level of transgene expression in the 
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infected cells [67]. Intracerebral injection offers the advantages of 
low toxicity, high local vector concentrations and localized 
transgene delivery but it does not allow wide viral vector 
distribution and requires invasive surgical intervention. Ubiquitous 
distribution of viral vectors in the CNS could be achieved by 
intrathecal or intraventricular injection but these methods do not 
permit spatial selectivity of delivery and require a large amount of 
vectors. Finally, intravascular viral vector applications do not 
require invasive surgical intervention but necessitate the use of high 
vector concentrations due to losses in peripheral organs such as the 
liver.  
Viral vectors represent a valid alternative for the generation of 
mouse models characterized by target gene over-expression over the 
classical transgene knock-in models. They allow transgene 
expression in a precise spatial-temporal manner in the desired 
animal strain and in a less time consuming manner. Viral vectors 
have been used to over-express alpha-synuclein (α-Syn), a 
Parkinson’s disease related protein, in the substantia nigra pars 
compacta of mice to generate an innovative PD mouse model. Viral 
vector-mediated α-Syn over-expression resulted in a rapid 
degeneration of nigrostriatal neurons, which was not previously 
observed by genetic mutations in mice [68]. Lentiviral-mediated 
over-expression of a mutated APP form in mouse hippocampus 
resulted in rapid Aβ accumulation and was employed to quickly 
investigate the therapeutic potential of Aβ protein suppression by 
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RNAi in the brain as novel treatment for AD [53]. However, the 
major drawbacks of viral-mediated gene transfer compared with 
gene knock-in in transgenic mice are the labor-intensive nature of 
the stereotactic injections, and the difficulty in obtaining widespread 
and controlled level of transgene expression. Viral vector-mediated 
over-expression can be employed also to investigate the effect of 
target gene expression on the behaviors or in a specific molecular 
pathway of knock-out mice. As example, an HSV1-based vector 
was used to analyze the effect of restoring the expression of Kv1.1 
protein in the hippocampus of Kv1.1 knock-out mice [69]. The 
functional role of α-synuclein in the dopamine synthesis was 
investigated though LV-α-Syn injection in dopaminergic neurons of 
α-Syn knockout mouse (ASKO) olfactory bulb. The LV-mediated 
over-expression of wild type α-Syn in the ASKO mice revealed the 
important role of this protein on TH regulation, dopamine synthesis, 
and cell viability [70]. 
Gene therapy holds great promise for the treatment of human 
disorders and the numerous applications of viral vectors in the last 
years have involved the validation of potential therapeutic 
approaches reversing the loss-of-function phenotype associated with 
numerous neurological diseases [71]. Several studies have been 
carried out in mouse models of neurological disorders to explore the 
efficacy of over-expressing potential therapeutic genes, in particular 
for the treatment of neurodegenerative disorders such as HD, PD 
and ALS. Many articles have been published in recent years 
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describing viral vector-mediated over-expression of various 
neurotrophic factors such as glial cell line-derived neurotrophic 
factor (GDNF) and brain derived neurotrophic factor (BDNF) for 
the potential treatment of Huntigton’s and Parkinson’s disease.  
AAV2-mediated GDNF over-expression in striatum of a pre-
symptomatic mouse model of HD ameliorated behavioral deficits on 
the accelerating rotorod and hind limb clasping tests and decreased 
the number of neurons containing mutant huntingtin-stained 
inclusion bodies, a characteristic of HD pathology [72]. Similarly, 
AAV-mediated over-expression of BDNF and GDNF has been 
shown to ameliorate the symptoms of an acute mouse model of HD 
[73]. These results open the possibility of using viral vector-
mediated delivery of neurotrophic factors as viable treatment for 
patients suffering from HD. The neuroprotective effect of GDNF in 
a murine model of Parkinson’s disease has also been demonstrated. 
In this study a lentiviral vector was used to over-express GDNF in 
the substancia nigra of a 6-hydroxydopamine (6-OHDA) model of 
Parkinson’s disease [74]. The same group employed lentiviral vector 
to over-express the antioxidant enzyme glutathione peroxidase 
(GPX) in nigral dopaminergic neurons prior to intrastriatal injection 
of the toxin 6-OHDA in mice. The authors reported a small but 
significant neuroprotection effect of GPX in these cells against 
drug-induced toxicity [75]. An alternative approach to delivering 
neurotrophic factors in the brain affected by neurodegenerative 
disorders is to directly activate the intracellular signaling pathways 
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responsible for their effects. Ries and colleagues used an AAV1 
vector to over-express the myristoylated, constitutively active form 
of the oncoprotein Akt/PKB in the substantia nigra of a murine 
model of Parkinson’s disease [76]. The Akt/PKB over-expression 
caused a pronounced neurotrophic and neuroprotective effect in the 
dopaminergic neurons of affected mice. The potential therapeutic 
effect of insulin-like growth factor 1 (IGF1) in retarding the 
progression of the fatal neurodegenerative disease ALS was 
investigated in symptomatic ALS mice. The injection of AAV-IGF1 
vectors in the deep cerebellar nuclei reduced ALS neuropathology 
and significantly extended life span in ALS mice [77]. Interestingly, 
systemic delivery of AAV-IGF1 vectors was also shown to improve 
motor function in a mouse model of diabetic peripheral neuropathy 
[78]. Viral vectors have also been successfully applied to develop 
novel treatments for muscular dystrophies (MDs) that are a 
heterogeneous group of inherited disorders characterized by 
progressive skeletal muscle degeneration. Several gene replacement 
and repair strategies mediated by viral vectors have been developed 
in mouse models of MDs, demonstrating the efficacy of this 
therapeutic strategy for the treatment of this class of disorders [79]. 
As example, the therapeutic potential of alpha-sarcoglycan gene 
(alpha-SG) replacement for patients suffering of limb-girdle 
muscular dystrophy type 2D (LGMD 2D) was investigated through 
AAV8-mediated alpha-SG expression in alpha-SG-deficient mice. A 
single intramuscular injection in the knock-out mice resulted in a 
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reversal of the muscle pathology and improvement in the contractile 
force [80]. 
Viral vector-mediated enzymatic complementation represents 
a promising treatment for those rare inherited neurodegenerative 
disorders characterized by the lack of single specific enzymes that 
lead to premature death. The efficacy of these novel genetic 
therapeutic approaches using viral vectors has been investigated in 
mouse models of the rare neurological inherited disorders 
Mucopolysaccharidosis (MPS) IIIB disease, Tay-Sachs (TS) 
disease, Niemann–Pick type A disease (NPA) and others. MPS IIIB 
is a lysosomal storage disease, caused by the deficiency of α-N-
acetylglucosaminidase (NaGlu) enzyme that leads to severe 
progressive neurological deficits and to premature death. 
Intravenous and intracisternal injection of AAV vector over-
expressing the NaGlu enzyme in young adult mice affected by MPS 
IIIB was shown to significantly prolong the lifespan and improved 
behavioral performances [81]. Tay-Sachs-related diseases are 
characterized by lysosomal storage of GM2 ganglioside caused by 
deficiency of α-hexosaminidase A, a heterodimeric protein. 
Intracranial inoculation of recombinant AAV vectors encoding the 
human β-hexosaminidase subunit genes, has been shown to increase 
the survival and improved the behavioral performance in a mouse 
model of Tay-Sachs disease [82]. Similarly, HSV-mediated 
expression of the hexosaminidase A alpha-subunit in the cerebellum 
and spinal cord of a TS animal model, through injection in the 
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internal capsule, restored the enzyme activity and abolished the 
GM2 ganglioside storage, without signs of viral vector toxicity [83]. 
AAV vectors were also used to express the therapeutic gene acid 
sphingomyelinase (ASM), which activity is lacking in the human 
Niemann–Pick type A disease, in the deep cerebellar nuclei of ASM 
knock-out mice, resulting in the reduction of storage pathology and 
correction of the behavioral deficits [84]. Taken all together, these 
studies indicate that viral vector-mediated expression of therapeutic 
genes has realistic potential for treating these rare human 
neurological genetic diseases that currently lack effective treatment. 
Viral vectors have been of huge value to investigate potential 
therapeutic approaches for the treatment of brain tumors [85]. The 
effect of different tumor suppressor genes in inhibiting growth of 
tumor xenografts in nude mice has been investigated by using both 
retrovirus- and adenovirus-mediated gene transfer. Adenovirus has 
been used to express the tumor suppressor gene phosphatase and 
tensin homologue (PTEN) in models of malignant astrocytoma 
bearing mutations in this gene. PTEN expression resulted in the 
blockade of both tumor invasiveness and angiogenesis [86]. Both 
retroviral and adenoviral vectors have been employed to mediate the 
expression of growth arrest specific-1 (GAS1) gene in astrocytoma 
xenografts in nude mice and both showed efficacy in inhibiting 
tumor growth [87,88]. Similarly, the effect of anti-angiogenic genes 
on tumor growth has been investigated by means of viral vector-
mediated over-expression. As example, AAV8-mediated expression 
 32
of an inhibitor of vascular endothelial growth factor (VEGF) 
reduced the tumor volume and increased the survival after injection 
in different mouse models of glioblastoma multiforme [89]. 
Recently, the potential of oncolytic replication-selective HSV as a 
new platform for brain cancer therapy, has been evaluated in nude 
mice bearing xenografts. These HSV-based vectors are 
characterized by mutations that bestow upon the virus the ability to 
selectively replicate in and lyse the dividing tumor cells. For 
example, the oncolytic HSV vector G47Δ efficiently induced 
regression of different forms of schwannoma tumor implanted 
subcutaneously in nude mice [90]. The efficacy and the safety of 
several oncolytic HSV vectors in human brain tumors have been 
already studied in several clinical trials but more efforts are needed 
to increase the therapeutic benefit of the treatment. Liu and 
colleagues investigate the potential of expressing onco-suppressor 
genes by oncolytic HSV to increase the therapeutic efficacy. The 
dominant-negative fibroblast growth factor (FGF) receptor 
(dnFGFR) has been expressed using an oncolytic HSV in glioma 
xenografts and has demonstrated increased efficacy in inhibiting 
tumor growth and angiogenesis compared to the standard oncolytic 
HSV [91]. Several gene therapy clinical trials are currently ongoing 
using viral vectors for the treatment of nervous system tumors and 
the possibility to combine viral vector-mediated gene therapy with 
classical treatments such as surgical and chemotherapeutic or 
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radiation treatments could significantly improve survival and the 
quality of life of human patients with brain tumors. 
 
3.2 Viral vector applications for transgenic mice 
Viral vectors can be used for the generation of more 
sophisticated conditional transgenic mice, using the Cre-loxP 
recombination strategy [92]. Exploring the functional role of a 
putative target gene is routinely carried out by means of transgenic 
mouse models, in which the target gene is either knock-down or 
knock-in. Brain-specific gene manipulation or modulation of the 
adult animal is likely to be required if the target gene is of 
neurological interest or if it is involved in the early developmental 
stages. Moreover, since the same gene may have different effects in 
different brain regions, the effect of the gene in a specific brain area 
may need to be shielded from effects in other areas. Several 
strategies have been developed over the past years to create 
conditional mouse models with specific temporal and spatial 
patterns of transgene expression such as combination of the Cre-
loxP system with tissue-specific or inducible promoters. However, 
these strategies do not allow transgene manipulation in a specific 
localized brain area. Infection of somatic tissues of loxP transgenic 
mice with a viral vector expressing Cre recombinase is a means of 
allowing flexible temporal-spatial control [93]. Since chronic 
antidepressant treatment was reported to increase BDNF expression 
in dentate gyrus (DG) but not in CA1 region of hippocampus, 
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Adachi and colleagues employed AAV-mediated Cre expression to 
investigate the role of BDNF in subregions of the hippocampus on 
the etiology of depression and anxiety [94]. They developed floxed 
mice in which BDNF was only deleted in the presence of Cre 
recombinase and delivered AAV-Cre virus specifically in dentate 
gyrus or CA1 regions of these transgenic mice. With this approach, 
they reported that selective loss of BDNF in either DG or CA1 did 
not induce depression-like behavior but that selective loss of BDNF 
in the DG but not the CA1 region reduced the response to 
antidepressant drugs. Similarly, the effect of NMDA receptors on 
seizure profile in hippocampal CA3 region was investigated by viral 
vector expression of Cre recombinase in loxP-GluRγ1 mice, 
obtained by inserting the loxP sites in the GluRγ1 gene [95]. The 
inducible ablation of NMDA receptors in the hippocampal CA3 
region of adult brain induced EEG spikes with larger amplitude 
compare to control and allowed to investigate the role of 
hippocampal CA3 NMDA receptors in controlling the excitability of 
the neural recurrent network oscillation. Moreover, viral vector-
mediated Cre expression was employed to develop a mouse model 
of Friedreich’s ataxia (FA), the most common of the hereditary 
ataxias characterized by mutations in the frataxin gene (frda). 
HSV1-Cre viruses were injected in the brainstem of loxP-frda mice 
to generate localized suppression of frataxin protein. These 
conditional knock-out mice developed a motor coordination deficit 
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that was recovered after injection with HSV-1 vectors expressing 
human frataxin gene [96].  
 
4. YAC, BAC, PAC and other vectors 
Transgenic animals expressing the gene of interest are 
commonly applied to the study of neurological disorders and a large 
effort has been made in recent last years to generate animal models 
resembling the pathological or physiological state in vivo as closely 
as possible [5]. One of the main problems encountered during the 
creation of transgenic mice is to control the expression of the 
transgene in order to mimic the in vivo state. In case of stochastic 
integration of the transgenic construct, the surrounding sequences in 
the host genome can modify the transgene expression pattern. In 
addition, most of the mammalian genes possess several regulatory 
sequences determining the final level of gene expression. The 
chromosomal position effect due by stochastic transgene integration 
can be overcome by targeting the site of integration by homologous 
recombination in ES cells. Moreover by adding all the regulatory 
sequences in the transgenic construct it is possible to obtain optimal 
transgene expression regardless of its position of integration. Since 
classical transgenic technologies are unable to introduce standard 
preparations of genomic fragments >40-50 kb, the ability to deliver 
vectors of large cloning capacity is required. These characteristics 
are present in artificial-chromosome type vectors such as yeast 
artificial chromosomes or YACs, bacterial artificial chromosomes or 
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BACs and P1-derived artificial chromosomes or PACs [97]. Thanks 
to their properties, these vectors have been extensively used over the 
past years to generate transgenic animals of use in the field of 
neurological disorders (Table 2). YACs are yeast artificial 
chromosomes with a DNA capacity of >2 Mb that are stably 
propagated in yeast as artificial chromosomes. Thanks to their large 
cloning capacity and the high versatility to genetic manipulation by 
homologous recombination in yeast, they are very attractive for 
gene transfer experiments. The main advantage that they present 
over standard cloning vectors is the possibility to ensure an optimal 
level of transgene expression, without positioning effect through 
providing all the regulatory elements of the transgene. Because of 
their large size, however, such cloning vectors are associated with 
several disadvantages such as the difficulty in handling, the insert 
instability and the complex process for advisable isolation of YAC 
from yeast chromosome. The bacterial artificial chromosomes are 
circular plasmid DNA molecules hosted in E.coli which can 
accommodate up to 300 Kb of foreign DNA while PACs are derived 
from the E.coli bacteriophage P1. Compared to YACs, BACs and 
PACs can be manipulated more easily but rearrangements and 
transgene fragmentations are still possible [98]. 
 
4.1 YACs, BACs and PACs for neurological transgenic mice 
Because of the potential to express transgenes in an 
appropriate spatial- and temporal-specific manner, large vectors 
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such as YACs, BACs and PACs have been extensively used to 
generate transgenic mice with the aim of generating improved 
animal models of human neurological disorders. In particular, both 
YACs and BACs have been extensively used to generate enhanced 
animal models of neurodegenerative disorders such as Huntington, 
Parkinson, SCA, Alzheimer and others (Table 2). Several 
independent groups applied YAC and BAC vectors to generate 
suitable mice models for examining the mechanism of 
neurodegeneration occurring in Huntington disease. As previously 
stated, human HD is caused by a trinucleotide CAG repeat 
expansion in the gene coding for htt translated into a polyglutamine 
stretch in the protein and the size of CAG expansion in the gene is 
directly proportional to the severity of the disease. YACs were used 
to express the human mutated form of huntingtin (htt). All the 
regulatory endogenous regions were included in the vectors together 
with the genomic sequence coding the mutated htt containing 
different numbers of copies of the CAG repeats. As in human 
disease, the severity of the disease increases with the size of CAG 
expansion in the YAC vector and in particular YAC128 mice (with 
128 polyglutamine repeats) present motor and cognitive deficits 
comparable with the human disease [99]. These animal models have 
been widely investigated to explore the mechanism underling the 
selective neurodegenerative process that resembles the process 
occurring in human HD patients [100]. For example, increased 
calpain activity in striatal medium-sized spiny neurons (MSNs) was 
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observed in YAC128 mice, suggesting that calpain could be 
involved in the NMDA-induced apoptosis occurring in MSNs of 
Huntington patients [101]. Similarly, BAC-mediated transgenic 
mouse models of Huntington disorder have been developed that 
express the human mutant form of huntingtin with 97 glutamine 
repeats under the control of the endogenous regulatory machinery 
[102]. YACs and BACs have been utilized to create transgenic mice 
models of spinocerebellar ataxia by using them to express the 
mutated form of the ataxin protein under control of its endogenous 
promoter and regulatory sequences [103,104]. These transgenic 
mice therefore represent an optimal model to investigate the 
degenerative process and possible therapeutic approaches. Superior 
genetic models of Alzheimer’s disease have been created using the 
YAC approach. Entire genomic copies of the human mutated APP 
or the mutated presenilin-1 (PS-1) genes, together with their 
regulatory elements have been introduced into transgenic mice. 
These animals were shown to develop many unique features 
characteristic of human AD that were not observed in other 
transgenic mouse models of AD [105]. Similarly, BAC transgenic 
mouse model of Parkinson disease was created by expressing a C-
terminal truncated human mutant parkin (Parkin-Q311X) in 
dopaminergic (DA) neurons under a dopamine transporter promoter 
[106]. This mouse model showed progressive hypokinetic motor 
deficits and degeneration of DA neurons in substantia nigra, 
demonstrating the toxic gain of function of parkin mutants. The 
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possibility to clone large fragment of genomic DNA has been 
extremely useful in cases in which the sequence of a particular gene 
is not known or when is necessary to investigate the effect of 
multiple genes as in the case of aneuploidy syndromes such as 
Down syndrome (DS). Several transgenic mice with YACs 
expressing part of the sequence of human chromosome 21 (HSA21) 
have been generated and their behavioral profile analyzed [107]. 
BAC containing the human DYRK1A gene located on human 
chromosome 21q22.2 was used to create a transgenic mouse model 
for the study of DS mental retardation. The transgenic mice 
exhibited significant impairment in spatial learning and memory 
tasks and alteration in hippocampal synaptic plasticity [108]. 
Taken together these studies demonstrate the validity of 
using YACs, BACs and other large cloning vectors to develop 
transgenic mice with a high level of transgene expression control, 
that represent invaluable animal models for the study of the 
pathogenesis and of the possible therapeutic strategies for 
neurological disorders.  
 
5. Mice versus other mammals 
Using mice to create suitable animal models for the study of 
specific disorders or to investigate the role of candidate genes has 
obvious advantages. First of all manipulation of the mouse genome 
to create specific genetic changes by microinjection of DNA into 
fertilized eggs or by homologous recombination in embryonic stem 
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cells is relatively easy compared to other mammalian species such 
as rats. Another advantage is the availability of “inbred strains” of 
mice that are genetically identical, obtained by breeding sibling 
mice over 20 generations. Since these animals present the same 
genetic background, they can be compared for the response to a 
treatment or a genetic modification between different laboratories 
[109]. However the choice of the genetic background in creating the 
animal model is a critical point that requires extensive consideration 
since different genetic traits could contribute in several ways to the 
mutant phenotype [110]. As described in this review, innovative 
technologies for gene expression manipulation, such as RNAi and/or 
viral vectors and DNA vectors such as YACs and BACs have been 
extensively applied in mice in order to create sophisticated animal 
models of great value in the study of human neurological disorders. 
Indeed, the human genome shares to a great extent the same genes 
as that of the mouse. Therefore, by engineering a genetic defect that 
causes a human neurological disease, into the mouse genome, is 
likely to result in the same disease in mice. Undeniably, numerous 
mice models of neurological disease that have been produced over 
recent years have developed many of the same symptoms and 
behavioral traits of human patients of neurological disorders [111]. 
In this context, RNAi and viral vectors have been applied to create 
even more sophisticated genetic manipulation in mice. It has been 
possible to analyze the effect of transgene expression modulation in 
specific spatial- and temporal-manner and to investigate the 
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potential of therapeutic approaches in pre-established mouse models 
of neurological disorders. For these reasons, mice represent one of 
the most exploited laboratory animal species in the field of 
neurological disease research. However, it has to be considered that 
genetic manipulation in mice could be associated with several 
disadvantages that could make it difficult to elucidate the phenotype 
associated with a specific genetic change [112]. As previously seen, 
one of these drawbacks is the variations of the behavioral phenotype 
deriving by the same genetic manipulation in different strain of 
mice. Moreover, the presence of a rich diversity of inbred mouse 
strains could complicate the analysis of the effects of target gene 
mutation. In addition, recent experimental evidences suggest that 
epigenetic changes can derive from the transmission of RNA or 
protein in the oocyte or sperm from transgenic parents to non-
transgenic offspring [112]. The presence of this phenomenon limits 
the use of non-transgenic littermates as controls only after careful 
comparison with wild-type mice. Moreover, from a physiological 
and psychological point of view, rats have been the organism of 
choice for decades and the first ever laboratory animal models used 
since their physiological processes are similar to humans and 
because their larger dimension compared to mice make them more 
suited to the application of invasive techniques such as cannula 
implantation, and carrying out physiological tests. In this context, 
the recent tools for genetic manipulation, RNA interference and 
 42
viral-vector transgene delivery, present the obvious advantage of 
being applicable not only to mice but also rats and other species.  
 
6. Conclusions and perspective 
Extensive research has been carried out in recent years to 
develop and apply innovative technologies for targeted gene 
manipulation. Since the first application of homologous 
recombination and DNA microinjection in mice, many attempts 
have been made to create more sophisticated models resembling the 
human pathological state or for further investigating the functional 
role of target genes. Transgenic mouse models have contributed 
largely to the understanding of the genetics of neurological disorders 
and to the development of therapeutic strategies. However, more 
robust and rapid methods for precise and specialized assessment of 
phenotype are required. Undoubtedly RNA interference has 
represented an innovative method for analysis of gene function 
through selective gene silencing and has been applied extensively to 
the study of neurological disorders. Besides its physiological role in 
controlling gene expression through miRNAs, it has provided an 
efficient tool for functional genomics and target validation 
processes. Using osmotic mini-pumps or in association with viral 
vectors, it has allowed us to investigate the role played by several 
genes in neurological disorders. At the same time, considerable 
effort has been made recently to investigate the therapeutic potential 
of RNAi in human neurological disorders. Novel therapeutic 
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approaches have been opened up for this wide class of disorders 
since RNAi has demonstrated therapeutic efficacy in several mouse 
models of human neurological states and clinical trials are already 
ongoing for other classes of disease. Several challenges face 
translation of RNAi to clinic, however, namely delivery and safety. 
Studies in mouse models will help in clarifying the effective 
potential of RNAi as a therapeutic strategy and to investigate 
possible side effects.  
Viral vectors represent another method of manipulating gene 
expression in adult mice and have been applied both in target gene 
validation and in the investigation of potential therapeutic strategies. 
Viral vector-based approaches differ from the standard transgenic 
method since they can mediate target gene manipulation in well 
defined regions of the adult CNS and they have been successfully 
used to generate advanced mice models of neurological disorders 
through over-expression of the disease-causing protein in specific 
brain regions or neuron populations. More significantly, several 
reports have recently been published describing efficacy of viral 
vector-mediated transgene expression in the treatment of 
neurological disorders in several mouse models. However the 
efficacy of viral vector-mediated gene manipulation to treat human 
neurological disorders needs intensive investigation due to the 
safety concerns associated even if it could represent a successful 
approach for progressive neurodegenerative conditions disorders 
that currently lack any effective treatments. Finally, large DNA 
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vectors such as YACs, BACs and PACs represent an innovative 
means of creating animal disease models that resemble the in vivo 
pathological state more closely, invaluable for investigating the 
efficacy and safety of novel therapeutic treatments. 
In conclusion, the advent of innovative methods for genetic 
manipulation has allowed the generation of superior mouse models 
that represent a considerable resource to investigate the pathogenesis 
and the therapeutic approaches in neurological disorders. 
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Fig. 1. Tools available for genetic manipulation in the mouse 
nervous system and their applications in the field of neurological 
disorders. 
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Fig. 2. The RNA interference pathway. a) Short interfering RNA: 
the siRNA is characterized by 5’ phosphorylated ends, a 19nt 
duplexed region and 2nt unpaired and unphosphorylated 3’ ends. 
This double stranded RNA molecule is recognized by the 
multiprotein complex RISC, which unwinds the siRNA duplex and 
incorporates the single stranded antisense strand. The antisense 
strand guides RISC to the target mRNA, driving its endonucleolytic 
cleavage. b). Short hairpin RNA: the siRNA is produced by the 
Dicer-mediated cleavage of longer dsRNA precursor molecules as 
those in the form of a hairpin structure. In the shRNA molecule the 
sense and antisense strands are separated by a loop sequence. This 
shRNA can be produced by the transcription of the shRNA 
construct mediated by Pol II or Pol III promoters. c) The microRNA 
pathway. Dicer cans also cleavage the ≈70nt hairpin miRNA 
precursor to produce the ≈22nt miRNA which is then incorporated 
in the miRNA-protein complex (miRNP). Unlike siRNAs, the 
miRNAs pair with partial sequence complementarity to the target 
mRNA and lead to translational repression or decrease mRNA 
stability.  
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Table 1 
Advantages and disadvantages of the different viral vectors most used for gene 
transfer in the nervous system. 
Viral vector    Advantages    Disadvantages   
Retroviral vectors   Large insert capacity for transgene (<7-
8kb).  
Broad cell tropism. 
Stable and high transgene expression.  
Relatively easy generation of high 
recombinant virus titers. 
No infection of non dividing 
cells. 
Possible insertional 
mutagenesis for random 
integration into host genome. 
Vector instability. 
Lentiviral vectors   Large insert capacity for transgene 
(10kb).  
Broad cell tropism. 
Infect dividing and non-dividing cells.  
Stable and high transgene expression.  
Possible insertional 
mutagenesis for random 
integration into host genome. 
 
Adenoviral vectors   Large insert capacity for transgene (7-
8kb).   
Broad cell tropism.    
Infect dividing and non-dividing cells.  
High transgene expression. 
Relatively easy generation of high 
recombinant virus titers. 
Immune response to viral 
proteins. 
Transient transgene 
expression.   
Adeno-associated 
viral vectors   
Broad cell tropism. 
Infect dividing and non-dividing cells.  
Prolonged and high transgene 
expression. 
Low immunogenicity and 
nonpathogenic.      
Limited capacity for transgene 
(4kb). 
Difficult generation of high 
virus titers. Requirement of 
helper virus for replication.  
Herpes simplex 
viral vectors   
Large insert capacity for transgene (up 
to 50kb).   
Broad cell tropism. 
Infect dividing and non-dividing cells.  
Generation of high recombinant virus 
titers.  
Natural tropism to neuronal cells. 
Possible toxicities. 
Risk of recombination.  
Transient transgene expression 
(prolonged in neurons).   
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Table 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transgenic mouse models of human neurological diseases generated with YACs, 
BACs or PACs.  
Human transgene Vector Human neurological 
disease 
Reference 
Huntingtin with 46, 72 and 
120 CAG 
repeats 
 
YAC Huntington disease [99-101] 
 
Huntingtin with 97 CAG 
repeats 
BAC Huntington disease [102] 
Ataxin 8 with 
[(CTA)3(CTG)5CCG(CTG)7(
CCG)(CTG)104] configuration 
BAC Spinocerebellar ataxia 
type 8 (SCA8) 
[103] 
Ataxin 3 with 15 and 84 CAG 
repeats 
YAC Spinocerebellar ataxia 
type 3 (SCA3) 
[104] 
APP YAC Alzheimer disease [105] 
Presenilin-1 YAC Alzheimer disease [113] 
Tau PAC Alzheimer disease [114] 
Parkin-Q311X BAC Parkinson disease [106]  
Chromosome 21 region 
21q22.2 
YAC Down's syndrome [107]  
DYRK1A BAC Down's syndrome [108] 
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